fampridine mr apotex fampridine 10mg modified release tablets blister pack
arrotex pharmaceuticals pty ltd - fampridine, quantity: 10 mg - tablet, modified release - excipient ingredients: magnesium stearate; colloidal anhydrous silica; macrogol 8000; polyvinyl alcohol; titanium dioxide; hypromellose; purified talc; microcrystalline cellulose - fampridine mr apotex modified release tablets are indicated for the symptomatic improvement of walking ability in adult patients with multiple sclerosis who have shown improvement after 8 weeks of treatment.
amisulpride scp amisulpride 50 mg uncoated tablet blister pack
southern cross pharma pty ltd - amisulpride, quantity: 50 mg - tablet, uncoated - excipient ingredients: sodium starch glycollate type a; lactose monohydrate; microcrystalline cellulose; magnesium stearate; hypromellose - amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.
amisulpride scp amisulpride 100 mg uncoated tablet blister pack
southern cross pharma pty ltd - amisulpride, quantity: 100 mg - tablet, uncoated - excipient ingredients: magnesium stearate; lactose monohydrate; sodium starch glycollate type a; hypromellose; microcrystalline cellulose - amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.
amisulpride scp amisulpride 200 mg uncoated tablet blister pack
southern cross pharma pty ltd - amisulpride, quantity: 200 mg - tablet, uncoated - excipient ingredients: sodium starch glycollate type a; lactose monohydrate; microcrystalline cellulose; hypromellose; magnesium stearate - amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.
amisulpride scp amisulpride 400 mg uncoated tablet blister pack
southern cross pharma pty ltd - amisulpride, quantity: 400 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; magnesium stearate; sodium starch glycollate type a; microcrystalline cellulose; hypromellose - amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.
amifampridine serb
serb sa - amifampridine phosphate - lambert-eaton myasthenic syndrome; paraneoplastic syndromes, nervous system; nervous system neoplasms; paraneoplastic syndromes; nervous system diseases; autoimmune diseases of the nervous system; neurodegenerative diseases; neuromuscular diseases; neuromuscular junction diseases; immune system diseases; autoimmune diseases; autoimmune diseases of the nervous system; cancer; neoplasms - other nervous system drugs - symptomatic treatment of lambert-eaton myasthenic syndrome (lems) in adults.
imidacloprid powder
wisdom pharmaceutical co.,ltd - imidacloprid (unii: 3bn7m937v8) (imidacloprid - unii:3bn7m937v8) - imidacloprid 1 kg in 1 kg
apo-amisulpride 100 mg tablet blister pack
arrotex pharmaceuticals pty ltd - amisulpride, quantity: 100 mg - tablet - excipient ingredients: sodium starch glycollate type a; lactose monohydrate; microcrystalline cellulose; methylcellulose; magnesium stearate - amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.
apo-amisulpride 200 mg tablet blister pack
arrotex pharmaceuticals pty ltd - amisulpride, quantity: 200 mg - tablet - excipient ingredients: magnesium stearate; microcrystalline cellulose; methylcellulose; lactose monohydrate; sodium starch glycollate type a - amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.
apo-amisulpride 50 mg tablet blister pack
arrotex pharmaceuticals pty ltd - amisulpride, quantity: 50 mg - tablet - excipient ingredients: lactose monohydrate; sodium starch glycollate type a; methylcellulose; magnesium stearate; microcrystalline cellulose - amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.